Sinco Pharmaceuticals Holdings Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Sinco Pharmaceuticals Holdings.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Healthcare earnings growth | 22.3% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
What Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 32% Share Price Gain Is Not Telling You
Oct 04
Risks To Shareholder Returns Are Elevated At These Prices For Sinco Pharmaceuticals Holdings Limited (HKG:6833)
Aug 16Some Investors May Be Willing To Look Past Sinco Pharmaceuticals Holdings' (HKG:6833) Soft Earnings
Apr 02Sinco Pharmaceuticals Holdings Limited (HKG:6833) Might Not Be As Mispriced As It Looks
Mar 08Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?
Nov 07A Look At The Intrinsic Value Of Sinco Pharmaceuticals Holdings Limited (HKG:6833)
Jun 26Does Sinco Pharmaceuticals Holdings (HKG:6833) Have A Healthy Balance Sheet?
May 30Sinco Pharmaceuticals Holdings (HKG:6833) Has A Pretty Healthy Balance Sheet
Oct 26Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Might Deserve Your Attention Today
Feb 04I Ran A Stock Scan For Earnings Growth And Sinco Pharmaceuticals Holdings (HKG:6833) Passed With Ease
Oct 25Little Excitement Around Sinco Pharmaceuticals Holdings Limited's (HKG:6833) Earnings
Jun 10Sinco Pharmaceuticals Holdings (HKG:6833) Could Easily Take On More Debt
May 24Here's Why I Think Sinco Pharmaceuticals Holdings (HKG:6833) Is An Interesting Stock
Apr 20We're Not So Sure You Should Rely on Sinco Pharmaceuticals Holdings' (HKG:6833) Statutory Earnings
Feb 16How Much Did Sinco Pharmaceuticals Holdings'(HKG:6833) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 11
Should You Be Excited About Sinco Pharmaceuticals Holdings Limited's (HKG:6833) 51% Return On Equity?
Dec 07In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sinco Pharmaceuticals Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | 2,977 | 47 | -363 | -340 | N/A |
| 3/31/2024 | 2,758 | 44 | -20 | 7 | N/A |
| 12/31/2023 | 2,540 | 42 | 324 | 354 | N/A |
| 9/30/2023 | 2,386 | 35 | 340 | 383 | N/A |
| 6/30/2023 | 2,232 | 27 | 355 | 413 | N/A |
| 3/31/2023 | 2,252 | 48 | 189 | 244 | N/A |
| 12/31/2022 | 2,272 | 69 | 22 | 75 | N/A |
| 9/30/2022 | 2,289 | 96 | 145 | 193 | N/A |
| 6/30/2022 | 2,307 | 122 | 268 | 312 | N/A |
| 3/31/2022 | 2,165 | 128 | 275 | 309 | N/A |
| 12/31/2021 | 2,024 | 135 | 282 | 306 | N/A |
| 9/30/2021 | 2,142 | 148 | 294 | 307 | N/A |
| 6/30/2021 | 2,261 | 161 | 305 | 308 | N/A |
| 3/31/2021 | 2,155 | 140 | 221 | 222 | N/A |
| 12/31/2020 | 2,050 | 118 | 137 | 137 | N/A |
| 9/30/2020 | 1,664 | 79 | -40 | -40 | N/A |
| 6/30/2020 | 1,277 | 41 | -218 | -217 | N/A |
| 3/31/2020 | 1,227 | 32 | -114 | -113 | N/A |
| 12/31/2019 | 1,176 | 24 | -10 | -10 | N/A |
| 9/30/2019 | 1,045 | -97 | 135 | 136 | N/A |
| 6/30/2019 | 915 | -217 | 281 | 281 | N/A |
| 3/31/2019 | 934 | -249 | 268 | 269 | N/A |
| 12/31/2018 | 953 | -281 | 255 | 256 | N/A |
| 9/30/2018 | 960 | -242 | 38 | 40 | N/A |
| 6/30/2018 | 966 | -203 | -179 | -177 | N/A |
| 3/31/2018 | 886 | -195 | N/A | -268 | N/A |
| 12/31/2017 | 807 | -186 | N/A | -359 | N/A |
| 9/30/2017 | 755 | -115 | N/A | -243 | N/A |
| 6/30/2017 | 704 | -43 | N/A | -127 | N/A |
| 3/31/2017 | 781 | -12 | N/A | -78 | N/A |
| 12/31/2016 | 859 | 19 | N/A | -30 | N/A |
| 9/30/2016 | 958 | 36 | N/A | -6 | N/A |
| 6/30/2016 | 1,057 | 52 | N/A | 17 | N/A |
| 3/31/2016 | 1,076 | 61 | N/A | 32 | N/A |
| 12/31/2015 | 1,096 | 70 | N/A | 46 | N/A |
| 9/30/2015 | 1,120 | 77 | N/A | 87 | N/A |
| 6/30/2015 | 1,144 | 84 | N/A | 128 | N/A |
| 3/31/2015 | 1,047 | 77 | N/A | 91 | N/A |
| 12/31/2014 | 950 | 69 | N/A | 53 | N/A |
| 12/31/2013 | 532 | 37 | N/A | 78 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 6833's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if 6833's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 6833's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 6833's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 6833's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 6833's Return on Equity is forecast to be high in 3 years time